Ground Truths

Jennifer Gunter & Eric Topol: Discuss Women’s Health and Recent Changes by FDA for MHT

Nov 28, 2025
In this discussion, Dr. Jennifer Gunter, a leading gynecologist and women's health advocate, teams up with Eric Topol to dive into the recent FDA changes regarding menopausal hormone therapy (MHT). They tackle complex issues like the misconceptions around MHT’s cognitive benefits and the impact of various hormone delivery methods on risks. Gunter critiques the wellness industry's marketing tactics and emphasizes the need for proper research funding in women's health. Their conversation highlights the intricate balance between symptom relief and informed care.
Ask episode
AI Snips
Chapters
Transcript
Episode notes
INSIGHT

FDA Messaging Overstated MHT Benefits

  • FDA messaging on MHT cherry-picked older, low-quality data and created propaganda.
  • Dr. Jennifer Gunter warns the recent PR framed as a major correction misrepresents the breadth of evidence.
INSIGHT

WHI Results Aren't Classwide For All MHT

  • WHI tested specific regimens not representative of modern practice, so blanket conclusions are limited.
  • Dr. Jennifer Gunter emphasizes results depend on formulation, route, and population studied.
INSIGHT

WHI Targeted The Real-World Patient Population

  • WHI deliberately enrolled older, postmenopausal women to answer if MHT prevents cardiovascular disease in that real-world use.
  • Dr. Jennifer Gunter notes the trial design matched prescribing practices at the time, so subgroup limits don't invalidate it.
Get the Snipd Podcast app to discover more snips from this episode
Get the app